DAEWON PHARMACEUTICAL CO.,LTD
003220 | KO
Overview
Corporate Details
- ISIN(s):
- KR7003220001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 성동구 천호대로 386 대원제약, 서울특별시
- Website:
- https://www.daewonpharm.com/eng
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-17 00:00 |
Regulatory Filings
[기재정정]투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
|
Korean | 24.0 KB | ||
| 2025-09-09 00:00 |
Transaction in Own Shares
자기주식처분결과보고서
|
Korean | 19.3 KB | ||
| 2025-09-09 00:00 |
Share Issue/Capital Change
유상증자또는주식관련사채등의발행결과(자율공시)
|
Korean | 6.0 KB | ||
| 2025-09-02 00:00 |
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
|
Korean | 34.4 KB | ||
| 2025-09-02 00:00 |
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
|
Korean | 31.4 KB | ||
| 2025-08-29 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 16.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
|
Korean | 13.7 KB | ||
| 2025-08-19 00:00 |
Share Issue/Capital Change
[기재정정]감자결정(종속회사의주요경영사항)
|
Korean | 20.0 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.7 MB | ||
| 2025-08-12 00:00 |
Share Issue/Capital Change
감자결정(종속회사의주요경영사항)
|
Korean | 16.1 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 946.4 KB | ||
| 2025-05-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (코대원플러스정 식품의약품안전처 국내 품목허가 신청)
|
Korean | 10.9 KB | ||
| 2025-05-23 00:00 |
Share Issue/Capital Change
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
|
Korean | 13.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.3 MB | ||
| 2025-04-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (DW4421 제3상 임상시험계획 승인신청(미란성))
|
Korean | 8.4 KB |
Automate Your Workflow. Get a real-time feed of all DAEWON PHARMACEUTICAL CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAEWON PHARMACEUTICAL CO.,LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAEWON PHARMACEUTICAL CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
South Korea
067290
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
United States of America
MENS
Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.
Japan
4556
Japan
4556
R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.
Japan
4521
Japan
4521
Developing stem cell-based biologics for rare and serious eye diseases.
United States of America
KALA
United States of America
KALA
Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.
United States of America
KLRS
United States of America
KLRS
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America
KALV
United States of America
KALV
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel
KMDA
Israel
KMDA
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America
KMDA
United States of America
KMDA